Teriflunomide

Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs 3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana • 28 Feb 2022
Comparative effectiveness and persistence of cladribine versus other oral DMTs in MS 1:11
Comparative effectiveness and persistence of cladribine versus other oral DMTs in MS
Namita Tundia • 25 Feb 2022
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs 1:57
COVID booster vaccines do not lead to humoral responses in patients with MS treated with DMTs
Celia Oreja-Guevara • 24 Feb 2022
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS 3:26
Phase III ULTIMATE I & II update: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman • 15 Oct 2021
Ublituximab: pending approval for relapsing MS 1:41
Ublituximab: pending approval for relapsing MS
Lawrence Steinman • 15 Oct 2021
Humoral response to COVID-19 vaccination in patients with MS 6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara • 14 Oct 2021
ULTIMATE I & II results: ublituximab versus teriflunomide in relapsing MS 3:27
ULTIMATE I & II results: ublituximab versus teriflunomide in relapsing MS
Lawrence Steinman • 11 Jun 2021
Managing pediatric MS in the current era 1:46
Managing pediatric MS in the current era
Tanuja Chitnis • 26 Apr 2021
Is long-term teriflunomide treatment safe in MS? 2:13
Is long-term teriflunomide treatment safe in MS?
Mark Freedman • 3 Mar 2021
TERIKIDS study: teriflunomide in pediatric patients with relapsing MS 2:12
TERIKIDS study: teriflunomide in pediatric patients with relapsing MS
Tanuja Chitnis • 24 May 2020
The content of VJNeurology is intended for healthcare professionals